1613589-23-3

Basic information

• Product Name: 4'-fluoro-2',3'-di-O-benzoyluridine
• Synonyms: 4'-fluoro-2',3'-di-O-benzoyluridine
• CAS NO: 1613589-23-3
• Molecular Weight: 470.411
• Mol File: 1613589-23-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4'-fluoro-2',3'-di-O-benzoyluridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-fluoro-2',3'-di-O-benzoyluridine(1613589-23-3)
• EPA Substance Registry System: 4'-fluoro-2',3'-di-O-benzoyluridine(1613589-23-3)

Safety Data

• Hazardous Substances Data: 1613589-23-3(Hazardous Substances Data)

Upstream product

• 1613589-22-2 5'-deoxy-5'-iodo-4'-fluoro-2',3'-di-O-benzoyluridine 
• 14365-63-0 5'-deoxyuridin-4'-ene 
• 1613589-21-1 5′-deoxy-5′-iodo-4′-fluorouridine 
• 14259-58-6 1-((2R,3R,4S,5S)-3,4-dihydroxy-5-iodomethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione 
• 58-96-8 uridine 

Downstream Products

• 1613589-28-8 C₂₆H₃₁FN₃O₁₀P 

Relevant articles and documents

Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′- C-methyluridine 5′-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection

We report the synthesis and biological evaluation of a series of 4′-fluoro-2′-C-substituted uridines. Triphosphates of the uridine analogues exhibited a potent inhibition of hepatitis C virus (HCV) NS5B polymerase with IC50 values as low as 27 nM. In an HCV subgenomic replicon assay, the phosphoramidate prodrugs of these uridine analogues demonstrated a very potent activity with EC50 values as low as 20 nM. A lead compound AL-335 (53) demonstrated high levels of the nucleoside triphosphate in vitro in primary human hepatocytes and Huh-7 cells as well as in dog liver following a single oral dose. Compound 53 was selected for the clinical development where it showed promising results in phase 1 and 2 trials.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.